ইউরোপীয় ইউনিয়ন -
স্লোভেনীয় -
EMA (European Medicines Agency)
levetiracetam teva
teva b.v. - levetiracetam - epilepsija - Živčni sistem - levetiracetam teva je označen kot monoterapije pri zdravljenju zasegov delno nastopa z ali brez sekundarnega posplošitev v odrasli in mladostniki, od 16 let z novo diagnosticirano epilepsijo. levetiracetam teva je označen kot adjunctive terapija:pri zdravljenju delno nastop napadi z ali brez sekundarne posplošitev pri odraslih, mladostnikih, otroke in dojenčke od 1 meseca starosti z epilepsijo;pri zdravljenju myoclonic zasegov v odrasle in mladostnike od 12. leta starosti z mladoletnimi myoclonic epilepsija;v zdravljenju primarne splošni tonik-clonic zasegov v odrasle in mladostnike od 12. leta starosti z idiopatsko splošnih epilepsijo.
ইউরোপীয় ইউনিয়ন -
স্লোভেনীয় -
EMA (European Medicines Agency)
mircera
roche registration gmbh - metoksi polietilen glikol-epoetin beta - anemia; kidney failure, chronic - antianemični preparati - treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adult patients (see section 5. treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (esa) after their haemoglobin level was stabilised with the previous esa (see section 5.
ইউরোপীয় ইউনিয়ন -
স্লোভেনীয় -
EMA (European Medicines Agency)
ontilyv
bial portela & companhia s.a. - opikapon - parkinsonova bolezen - anti-parkinsonska zdravila - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.
ইউরোপীয় ইউনিয়ন -
স্লোভেনীয় -
EMA (European Medicines Agency)
pombiliti
amicus therapeutics europe limited - cipaglucosidase alfa - bolezen tipa ii za shranjevanje glikogena - drugi zdravljene bolezni prebavil in presnove izdelki, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).
ইউরোপীয় ইউনিয়ন -
স্লোভেনীয় -
EMA (European Medicines Agency)
opfolda
amicus therapeutics europe limited - miglustat - bolezen tipa ii za shranjevanje glikogena - drugi proizvodi prebavnega trakta in metabolizma - opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset pompe disease (acid α- glucosidase [gaa] deficiency).